All In Biotech

Drug Trial Radar · NCT06618196

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

A Phase II, Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Immunogenicity and Safety of DTaP-HepB-IPV-Hib Hexavalent Vaccine LR20062 Versus Hexaxim Administered Intramuscularly in Healthy Infants As Primary Series At 2, 4, 6 Months of Age

Last checked: Nov 19, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

336

Planned (sponsor's estimate)

Start

Oct 2, 2024

Primary completion

Jun 30, 2025

Study completion Apr 30, 2026

Sponsor

Lead sponsor
LG ChemIndustry
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 days, up to 70 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.

Conditions

  • Diphtheria
  • Tetanus
  • Pertussis
  • Hepatitis B
  • Poliomyelitis
  • Haemophilus Influenzae Type B Infection

Interventions

  • LR20062Biological

    DTaP-HepB-IPV-Hib vaccine

  • DTaP-HepB-IPV-Hib vaccineBiological

    Control hexavalent vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroprotection/vaccine-response rateTime frame: 1 month after the third dose primary series

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.